Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Equity Ratio (2016 - 2025)

Spero Therapeutics' Equity Ratio history spans 10 years, with the latest figure at 0.86 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 105.25% year-over-year to 0.86; the TTM value through Dec 2025 reached 0.86, up 105.25%, while the annual FY2025 figure was 0.86, 105.25% up from the prior year.
  • Equity Ratio reached 0.86 in Q4 2025 per SPRO's latest filing, up from 0.49 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.86 in Q4 2025 to a low of 0.42 in Q4 2024.
  • Average Equity Ratio over 5 years is 0.58, with a median of 0.55 recorded in 2024.
  • Peak YoY movement for Equity Ratio: plummeted 48.3% in 2022, then surged 105.25% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.52 in 2021, then grew by 17.89% to 0.61 in 2022, then decreased by 3.68% to 0.59 in 2023, then decreased by 28.81% to 0.42 in 2024, then soared by 105.25% to 0.86 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Equity Ratio are 0.86 (Q4 2025), 0.49 (Q3 2025), and 0.53 (Q2 2025).